Back to Browse Journals » Core Evidence » Volume 2 » Issue 3

Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome

Authors Mark Waterlow, Paul Chrisp

Published Date February 2008 Volume 2007:2(3) Pages 0—0

DOI http://dx.doi.org/10.2147/CE.S7428

Published 29 February 2008

Mark Waterlow, Paul Chrisp

Core Medical Publishing, Knutsford, UK

Introduction: Obesity and overweight affect over 1 billion people worldwide and are leading causes of morbidity and mortality. Clinical features of obesity converge with those of the metabolic syndrome and type 2 diabetes, greatly increasing the risk of long-term adverse outcomes.

Aims: To review the evidence on rimonabant, a novel CB1 receptor antagonist, for the treatment of obese and overweight patients.

Evidence review: There is clear evidence that rimonabant 20 mg/day in conjunction with a hypocaloric diet causes a mean weight loss of 4.6 kg in obese and overweight patients after 1 year’s treatment, with approximately 50% of patients achieving a weight loss of ≥5%. One study demonstrated that weight loss is maintained for up to 2 years. The drug also improves lipid and glycemic cardiovascular risk factors, including high-density lipoprotein cholesterol and insulin resistance, and reduces waist circumference, thus reducing the prevalence of metabolic syndrome. Treatment of obese and overweight diabetic patients with rimonabant decreases glycosylated hemoglobin (HbA1c), including patients previously untreated for diabetes. The effect of rimonabant appears to be partly independent of weight loss. Rimonabant 20 mg/day is generally well tolerated, with mild to moderate transient adverse effects including nausea, diarrhea, dizziness, and anxiety. Approximately 14% of patients receiving rimonabant 20 mg/day discontinued due to adverse effects, primarily depressed mood, although overall rates of depression did not differ significantly compared with placebo.

Place in therapy: The evidence supports the use of rimonabant 20 mg/day along with dietary modification to reduce cardiovascular risk factors in obese and overweight patients, including those with diabetes. The drug is contraindicated in patients receiving antidepressants. Long-term data on cardiovascular outcomes, morbidity, and mortality are eagerly awaited.

Key words: metabolic syndrome, obesity, rimonabant, type 2 diabetes

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus

Louise Profit, Paul Chrisp, Carole Nadin

Core Evidence 2008, 3:0-0

Published Date: 31 December 2008

Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis

Louise Profit, Paul Chrisp

Core Evidence 2007, 2:0-0

Published Date: 30 November 2007

Maraviroc: the evidence for its potential in the management of HIV

Louise Profit

Core Evidence 2007, 2:0-0

Published Date: 31 March 2007

Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer

Sonya Haslam, Paul Chrisp

Core Evidence 2007, 2:0-0

Published Date: 31 March 2007

Etanercept in psoriasis: the evidence of its therapeutic impact

Andrew Thomson

Core Evidence 2007, 2:0-0

Published Date: 31 March 2007

Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting

Paul Chrisp

Core Evidence 2007, 2:0-0

Published Date: 31 March 2007

Perindopril: the evidence of its therapeutic impact in hypertension

Andrew Thomson, Mary Greenacre

Core Evidence 2007, 2:0-0

Published Date: 31 March 2007

Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia

Louise Profit

Core Evidence 2006, 1-Issues 3 & 4:0-0

Published Date: 30 June 2006

Ciclesonide in persistent asthma: the evidence of its therapeutic value

Charlotte A. Kenreigh, Linda Timm Wagner, Paul Chrisp

Core Evidence 2006, 1-Issues 3 & 4:0-0

Published Date: 30 June 2006

Aripiprazole: the evidence of its therapeutic impact in schizophrenia

William Winlow, Louise Profit, Paul Chrisp

Core Evidence 2006, 1-Issues 3 & 4:0-0

Published Date: 30 June 2006

Bortezomib: the evidence of its clinical impact in multiple myeloma

Simon Lancaster

Core Evidence 2006, 1-Issues 3 & 4:0-0

Published Date: 30 June 2006

K-111: the emerging evidence for its potential in the treatment of the metabolic syndrome

Margaret Duggan-Keen

Core Evidence 2006, 1-Issues 3 & 4:0-0

Published Date: 31 March 2006

Donepezil in Alzheimer’s disease: an evidence-based review of its impact on clinical and economic outcomes

Joanne Knowles

Core Evidence 2006, 1-Issues 3 & 4:0-0

Published Date: 31 March 2006

FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value

Andrew Thomson

Core Evidence 2006, 1-Issues 3 & 4:0-0

Published Date: 31 March 2006

Lapatinib: the evidence for its therapeutic value in metastatic breast cancer

Andrew Thomson

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 30 June 2005

Exubera® (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetes

Louise Profit

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 30 June 2005

Topiramate: the evidence for its therapeutic value in the prevention of migraine

Carole Nadin

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 30 June 2005

Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia

Andrew Thomson

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 30 June 2005

Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction

Carole Nadin

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 30 June 2005

Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia

Sonya Haslam

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 31 March 2005

Aliskiren in hypertension: evidence for its potential therapeutic value

Doris Peter

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 31 March 2005

Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes

William Winlow

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 31 March 2005

Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value

Carole Nadin

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 31 March 2005

Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes

Andrew Thomson

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 31 March 2005

Readers of this article also read:

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T

Clinical Pharmacology: Advances and Applications 2014, 6:51-59

Published Date: 19 March 2014

Population pharmacokinetics of olprinone in healthy male volunteers

Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H

Clinical Pharmacology: Advances and Applications 2014, 6:43-50

Published Date: 4 March 2014

Facial transplantation: a review of ethics, progress, and future targets

Edwards JA, Mathes DW

Transplant Research and Risk Management 2011, 3:113-125

Published Date: 5 September 2011

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011

Eggshell membrane: A possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies

Kevin J Ruff, Dale P DeVore, Michael D Leu, Mark A Robinson

Clinical Interventions in Aging 2009, 4:235-240

Published Date: 18 May 2009